Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

BI licenses Lupin's MEK inhibitor
Boehringer Ingelheim (Ingelheim, Germany) licensed development and commercialization rights to MEK inhibitor LNP3794 from Lupin Ltd. (NSE:LUPIN; BSE:500257), which the pharma plans to test in combination with

Read the full 325 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE